Case Reports

SARS-CoV-2: A Novel Precipitant of Ischemic Priapism

Author and Disclosure Information

Background: Priapism is a disorder that occurs when the penis maintains a prolonged erection in the absence of appropriate stimulation. Conditions that result in hypercoagulable states and hyperviscosity are associated with ischemic priapism. COVID-19 is increasingly associated with coagulopathy. To date, there are 6 reported cases of priapism occurring in patients with COVID-19, 5 occurring in the setting of critical illness.

Case Presentation: We present a case of ischemic priapism which we suspect resulted from COVID-19–associated coagulopathy in a patient without severe COVID-19 presentation.

Conclusions: A lthough there have been only a handful of reported cases of COVID-19–associated coagulopathy leading to ischemic priapism, it is possible that the true incidence is much higher. While our case highlights the importance of considering COVID-19 infection in the differential diagnosis of ischemic priapism, more research is needed to understand incidence and definitively establish a causative relationship.


 

References

Priapism is a disorder that occurs when the penis maintains a prolonged erection in the absence of appropriate stimulation. The disorder is typically divided into subgroups based on arterial flow: low flow (ischemic) and high flow (nonischemic). Ischemic priapism is the most common form and results from venous congestion due to obstructed outflow and inability of cavernous smooth muscle to contract, resulting in compartment syndrome, tissue hypoxia, hypercapnia, and acidosis.1 Conditions that result in hypercoagulable states and hyperviscosity are associated with ischemic priapism. COVID-19 is well known to cause an acute respiratory illness and systemic inflammatory response and has been increasingly associated with coagulopathy. Studies have shown that 20% to 55% of patients admitted to the hospital for COVID-19 show objective laboratory evidence of a hypercoagulable state.2

To date, there are 6 reported cases of priapism occurring in the setting of COVID-19 with all cases demonstrating the ischemic subtype. The onset of priapism from the beginning of infectious symptoms ranged from 2 days to more than a month. Five of the cases occurred in patients with critical COVID-19 and 1 in the setting of mild disease.3-8 Two critically ill patients did not receive treatment for their ischemic priapism as they were transitioned to expectant management and/or comfort measures.Most were treated with cavernosal blood aspiration and intracavernosal injections of phenylephrine or ethylephrine. Some patients were managed with prophylactic doses of anticoagulation after the identification of priapism; others were transitioned to therapeutic doses. Two patients were followed postdischarge; one patient reported normal nighttime erections with sexual desire 2 weeks postdischarge, and another patient, who underwent a bilateral T-shunt procedure after unsuccessful phenylephrine injections, reported complete erectile dysfunction at 3 months postdischarge.4,7 There was a potentially confounding variable in 2 cases in which propofol infusions were used for sedation management in the setting of mechanical ventilation.6,8 Propofol has been linked to priapism through its blockade of sympathetic activation resulting in persistent relaxation of cavernosal smooth muscle.9 We present a unique case of COVID-19–associated ischemic priapism as our patient had moderate rather than critical COVID-19.

Pages

Recommended Reading

FDA panel backs adding Omicron component to COVID boosters
Federal Practitioner
A Learning Health System Approach to Long COVID Care
Federal Practitioner
What are the benefits of a fourth vaccination against COVID?
Federal Practitioner
Skin reactions after COVID-19 vaccination have six patterns
Federal Practitioner
Experimental cancer drug promising for hospitalized COVID patients
Federal Practitioner
WHO tracking new Omicron subvariant in India
Federal Practitioner
U.S. allows pharmacists to prescribe Paxlovid directly
Federal Practitioner
Obesity links to faster fading of COVID vaccine protection
Federal Practitioner
BA.4 and BA.5 subvariants are more evasive of antibodies, but not of cellular immunity
Federal Practitioner
Shift schedule today could worsen that stroke tomorrow
Federal Practitioner